In an analysis of 22 pharmaceutical companies that merged between 1988 and 1999, Boston-based CenterWatch found that clinical research spending and productivity declined sharply in the three years following a merger.
In an analysis of 22 pharmaceutical companies that merged between 1988 and 1999, Boston-based CenterWatch found that clinical research spending and productivity declined sharply in the three years following a merger.
Results of the CenterWatch analysis show that merged companies curtail research and development spending dramatically during the three years immediately following a merger as they trim their drug pipelines. Three years after companies merge, the average number of development projects - preclinical through phase III - declines by 34% below cumulative pre-merger company levels, according to the CenterWatch analysis.
"This analysis suggests that in the first several years after consolidating, major pharmaceutical companies are not achieving critical productivity objectives," said Ken Getz, president and CEO of CenterWatch. "It is widely recognized that companies will need to double the level of innovation in order to sustain their growth in revenue and earnings. In the short term, mergers are not meeting certain strategic research and development objectives and may even harm the industry's longer-term ability to innovate," he said.
Annick de Bruin, CenterWatch's research manager, added that in this industry, perceptions may not reflect short-term reality. "A number of professionals believe that, in the long run, mergers create better companies," he said. "But in the short term, these megamergers cause disruptions in internal operations and project cancellations with contract research organizations and with investigative sites." PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.